Literature DB >> 28347225

Magnetic resonance imaging tumor regression shrinkage patterns after neoadjuvant chemotherapy in patients with locally advanced breast cancer: Correlation with tumor biological subtypes and pathological response after therapy.

Laura Ballesio1, Silvia Gigli1, Francesca Di Pastena1, Guglielmo Giraldi2, Lucia Manganaro1, Emanuela Anastasi3, Carlo Catalano1.   

Abstract

The objective of this study is to analyze magnetic resonance imaging shrinkage pattern of tumor regression after neoadjuvant chemotherapy and to evaluate its relationship with biological subtypes and pathological response. We reviewed the magnetic resonance imaging studies of 51 patients with single mass-enhancing lesions (performed at time 0 and at the II and last cycles of neoadjuvant chemotherapy). Tumors were classified as Luminal A, Luminal B, HER2+, and Triple Negative based on biological and immunohistochemical analysis after core needle biopsy. We classified shrinkage pattern, based on tumor regression morphology on magnetic resonance imaging at the II cycle, as concentric, nodular, and mixed. We assigned a numeric score (0: none; 1: low; 2: medium; 3: high) to the enhancement intensity decrease. Pathological response on the surgical specimen was classified as complete (grade 5), partial (grades 4-3), and non-response (grades 1-2) according to Miller and Payne system. Fisher test was used to relate shrinkage pattern with biological subtypes and final pathological response. Seventeen patients achieved complete response, 25 partial response, and 9 non-response. A total of 13 lesions showed nodular pattern, 20 concentric, and 18 mixed. We found an association between concentric pattern and HER2+ (p < 0.001) and mixed pattern and Luminal A lesions (p < 0.001). We observed a statistical significant correlation between concentric pattern and complete response (p < 0.001) and between mixed pattern and non-response (p = 0.005). Enhancement intensity decrease 3 was associated with complete response (p < 0.001). Shrinkage pattern and enhancement intensity decrease may serve as early response indicators after neoadjuvant chemotherapy. Shrinkage pattern correlates with tumor biological subtypes.

Entities:  

Keywords:  Tumor biological subtypes; breast magnetic resonance imaging; neoadjuvant chemotherapy; shrinkage pattern; tumor regression

Mesh:

Substances:

Year:  2017        PMID: 28347225     DOI: 10.1177/1010428317694540

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  11 in total

1.  Mid-treatment Ultrasound Descriptors as Qualitative Imaging Biomarkers of Pathologic Complete Response in Patients with Triple-Negative Breast Cancer.

Authors:  Rosalind P Candelaria; Beatriz E Adrada; Deanna L Lane; Gaiane M Rauch; Stacy L Moulder; Alastair M Thompson; Roland L Bassett; Elsa M Arribas; Huong T Le-Petross; Jessica W T Leung; David A Spak; Elizabeth E Ravenberg; Jason B White; Vicente Valero; Wei T Yang
Journal:  Ultrasound Med Biol       Date:  2022-03-14       Impact factor: 2.998

2.  Surgical margin status and survival outcomes of breast cancer patients treated with breast-conserving surgery and whole-breast irradiation after neoadjuvant chemotherapy.

Authors:  Jong-Ho Cheun; Young Joo Lee; Jun-Hee Lee; Yungil Shin; Jung Whan Chun; Soo Yeon Baek; Hong-Kyu Kim; Han-Byoel Lee; Jonghan Yu; Byung Joo Chae; Wonshik Han; Jeong Eon Lee
Journal:  Breast Cancer Res Treat       Date:  2022-06-28       Impact factor: 4.624

3.  Role of Magnetic Resonance Imaging in the Evaluation of Breast Cancer Response to Neoadjuvant Chemotherapy.

Authors:  Giorgia Pasquero; Alessandra Surace; Antonio Ponti; Massimiliano Bortolini; Donatella Tota; Maria Piera Mano; Riccardo Arisio; Chiara Benedetto; Maria Grazia Baù
Journal:  In Vivo       Date:  2020 Mar-Apr       Impact factor: 2.155

4.  MRI-based response patterns during neoadjuvant chemotherapy can predict pathological (complete) response in patients with breast cancer.

Authors:  Briete Goorts; Kelly M A Dreuning; Janneke B Houwers; Loes F S Kooreman; Evert-Jan G Boerma; Ritse M Mann; Marc B I Lobbes; Marjolein L Smidt
Journal:  Breast Cancer Res       Date:  2018-04-18       Impact factor: 6.466

5.  Mutant Allele Frequency-Based Intra-Tumoral Genetic Heterogeneity Related to the Tumor Shrinkage Mode After Neoadjuvant Chemotherapy in Breast Cancer Patients.

Authors:  Chun-Hui Zheng; Zhao-Yun Liu; Chen-Xi Yuan; Xiao-Yun Dong; Hai-Mei Li; Jin-Jin Wang; Zhao-Peng Zhang; Hong-Ying Liu; Xiao-Yan Ding; Wendy Wu; Rui-Ru Wang; Yong-Sheng Wang
Journal:  Front Med (Lausanne)       Date:  2021-03-31

6.  Meta-Analysis of Shrinkage Mode After Neoadjuvant Chemotherapy for Breast Cancers: Association With Hormonal Receptor.

Authors:  Chun-Hui Zheng; Kai Xu; Wen-Ping Shan; Ya-Kun Zhang; Zhi-De Su; Xiang-Jin Gao; Yu-Jue Wang; Jian-Yu Qi; Xiao-Yan Ding; Chun-Ping Wang; Yong-Sheng Wang
Journal:  Front Oncol       Date:  2022-04-04       Impact factor: 5.738

7.  Prediction of Tumor Shrinkage Pattern to Neoadjuvant Chemotherapy Using a Multiparametric MRI-Based Machine Learning Model in Patients With Breast Cancer.

Authors:  Yuhong Huang; Wenben Chen; Xiaoling Zhang; Shaofu He; Nan Shao; Huijuan Shi; Zhenzhe Lin; Xueting Wu; Tongkeng Li; Haotian Lin; Ying Lin
Journal:  Front Bioeng Biotechnol       Date:  2021-07-06

8.  Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).

Authors:  Simon Peter Gampenrieder; Andreas Peer; Christian Weismann; Matthias Meissnitzer; Gabriel Rinnerthaler; Johanna Webhofer; Theresa Westphal; Marina Riedmann; Thomas Meissnitzer; Heike Egger; Frederike Klaassen Federspiel; Roland Reitsamer; Cornelia Hauser-Kronberger; Katharina Stering; Klaus Hergan; Brigitte Mlineritsch; Richard Greil
Journal:  Breast Cancer Res       Date:  2019-01-31       Impact factor: 6.466

9.  Association of the genetic variants (-794 CATT5-8 and -173 G > C) of macrophage migration inhibitory factor (MIF) with higher soluble levels of MIF and TNFα in women with breast cancer.

Authors:  Guadalupe Avalos-Navarro; Alicia Del Toro-Arreola; Adrián Daneri-Navarro; Antonio Quintero-Ramos; Luis Alberto Bautista-Herrera; Ramon Antonio Franco Topete; Brian Uriel Anaya Macias; David Israel Javalera Castro; Andrés de Jesús Morán-Mendoza; Antonio Oceguera-Villanueva; Antonio Topete-Camacho; José Francisco Muñoz-Valle
Journal:  J Clin Lab Anal       Date:  2020-01-24       Impact factor: 2.352

10.  Correlation between MRI morphological response patterns and histopathological tumor regression after neoadjuvant endocrine therapy in locally advanced breast cancer: a randomized phase II trial.

Authors:  Joana Reis; Owen Thomas; Maryam Lahooti; Marianne Lyngra; Hossein Schandiz; Joao Boavida; Kjell-Inge Gjesdal; Torill Sauer; Jürgen Geisler; Jonn Terje Geitung
Journal:  Breast Cancer Res Treat       Date:  2021-08-06       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.